Pharmacological properties of ketamine

Drug and Alcohol Review

Volumn 15, Issue 2, 1996, Pages 145-155

  White, Jason M ^a   Ryan, Christina F ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Ketamine; Recreational drugs

Indexed keywords

EID: 0030541935     PISSN: 09595236     EISSN: None     Source Type: Journal    
DOI: 10.1080/09595239600185801     Document Type: Review

References (69)

1. Jansen R. Non-medical use of ketamine. Br Med J 1993;306:601-602.
2. Australian Bureau of Criminal Intelligence. Australian Drug Intelligence Assessment, 1993. Canberra: ACT, 1993.
3. Reier C. Ketamine - "dissociative agent" or hallucinogen? [Letter] New Engl J Med 1971;791-792.
4. White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982;56:119-136.
5. Domino EF. History and pharmacology of PCP and PCP-related analogs. In: Smith D, Wesson DR, Buxton ME, Seymour RB, Ross S, Bishop MP, Zerkin E, eds. PCP: problems and prevention. Iowa: Kendall/Hunt Publishing Company, 1982:37-41.
6. Schnoll SH. Street PCP scene: issues on synthesis and contamination. In: Smith D, Wesson DR, Buxton ME, Seymour RB, Ross S, Bishop MP, Zerkin E, eds. PCP: problems and prevention. Iowa: Kendall/Hunt Publishing Company, 1982:42-46.
7. Kothary SP, Zsigmond EK. A double-blind study of the effective anti-hallucinatory doses of diazepam prior to ketamine anesthesia. Clin Pharmacol Ther 1977;21:108-109.
8. Barron P, Arens JF. Ketamine as an induction anesthetic for poor-risk patients. Southern Med J 1974; 67:1398-1402.
9. Tweed WA, Minuck M, Mymin D. Circulatory responses to ketamine. Anesthesiology 1972;37: 613-619.
10. Ivankovich AD, Miletich DJ, Reimann C, Albrecht RF, Zahed B. Cardiovascular effects of centrally administered ketamine in goats. Anesth Analg 1974; 53:924-933.
11. Pagel PS, Kampine JP, Schmeling WT, Warltier DC. Ketamine depresses mycardial contractility as evaluated by the preload recruitable stroke work relationship in chronically instrumented dogs with autonomie nervous system blockade. Anesthesiology 1992;76:564-572.
12. Zsigmond EK, Matsudi A, Kothary SP, Jallad M. Arterial hypoxemia caused by intravenous ketamine. Anesth Analg (Cleve) 1976;55:311-314.
13. Sarma VJ. Use of ketamine in acute severe asthma. Acta Anaesthesiol Scand 1992;36:106-107.
14. Øye I Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 1992; 260:1209-1213.
15. Hansen G, Jensen SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs 1988;20:419-425.
16. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC. Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharm 1985;5:70-77.
17. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Arch Gen Psychiatr 1994;51:199-214.
18. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799-812.
19. Jansen KLR. Neuroscience and the near-death experience: roles for the NMDA-PCP receptor, the sigma receptor and the endopsychosins. Med Hypoth 1990;31:25-29.
20. Fine J, Finestone SC. Sensory disturbances following ketamine anesthesia: recurrent hallucinations. Anesth Analg 1973;52:428-430.
21. Perel A, Davidson JT. Recurrent hallucinations following ketamine. Anaesthesia 1976;31:1081-1083.
22. Harris AJ, Biersner RJ, Edwards D, Bailey LW. Attention, learning and personality during ketamine emergence. Anesth Analg 1975;54:169-172.
23. Jackson A, Koek W, Colpaert FC. NMDA antagonists make learning and recall state dependent. Behav Pharmacol 1992;3:415-421.
24. Meliska CJ, Greenberg AJ, Trevor AJ. The effects of ketamine enantiomers on schedule-controlled behavior in the rat. J Pharmacol Exp Ther 1980;212: 198-202.
25. Marietta MP, Way WL, Castagnoli N, Trevor AJ. On the pharmacology of the ketamine enantiomorphs in the rat. J Pharmacol Exper Ther 1977; 202:157-165.
26. White JM, Smith AM. Modification of the behavioural effects of ethanol by nifedipine. Alcohol Alcoholism 1992;27:137-141.
27. Wenger GR, Dews PB. The effects of phencyclidine, ketamine, d-amphetamine and pentobarbital on schedule-controlled behavior in the mouse. J Pharmacol Exp Ther 1976;196:616-624.
28. Wenger GR. The effect of phencyclidine and ketamine on schedule-controlled behavior in the pigeon. J Pharmacol Exp Ther 1976;196:172-179.
29. Moreton JE, Meisch RA, Stark L, Thompson T. Ketamine self-administration by the rhesus monkey. J Pharmacol Exp Ther 1977;203:303-309.
30. Balster RL, Johanson CE, Harris RT, Schuster CR. Phencylcidine self-administration in the rhesus monkey. Pharmacol Biochem Behav 1973;1:167-172.
31. Pickens R, Thompson T, Muchow D. Cannabis and phencylidine self-administration by animals. In: Goldberg I, Hoffmeister F, eds. Psychic Dependence. Berlin: Springer-Verlag, 1973:78-86.
32. White PF, Ham J, Way WL, Trevor AJ. Pharmacology of ketamine isomers in surgical patients. Anesthesiology 1980;52:231-239.
33. Haas, DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog 1992;39:61-68.
34. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 1981;53:805-809.
35. Marietta MP, White PF, Pudwill CR, Way WL, Trevor AJ. Biodisposition of ketamine in the rat: self-induction of metabolism. J Pharmacol Exp Ther 1976;196:536-564.
36. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatr 1991;148:1301-1308.
37. Holtzman SG. Drug discrimination studies. Drug Alc Depend 1985;14:263-282.
38. Johnson KM, Jones SM. Neuropharmacology of phencyclidine. Ann Rev Pharmacol Toxicol 1990; 30:707-750.
39. Willetts J, Balster RL, Leander JD. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 1990;11:423-428.
40. Koek W, Woods JH, Colpaert FC. N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis. J Pharmacol Exper Ther 1990;253:1017-1025.
41. Koek W, Colpaert FC, Woods JH, Kamenka J-M. The phencyclidine (PCP) analog N-[1])2-benzo (B)thiophenyl)cyclohexyl] piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801. J Pharmacol Exp Ther 1989;250:1019-1027.
42. Thompson DM, Winsauer PJ, Mastropaolo J. Effects of phencyclidine, ketamine and MDMA on complex operant behavior in monkeys. Pharmacol Biochem Behav 1987;26:401-405.
43. Butelman ER. A novel NMDA antagonist, MK-801, impairs performance in a hippocampal-dependent spatial learning task. Pharmacol Biochem Behav 1989;34:13-16.
44. Liljequist S. Genetic differences in the effects of competitive and non-competitive NMDA receptor antagonists on locomotor activity in mice. Psychopharmacology 1991;104:17-21.
45. Su T-P. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit Rev Neurobiol 1993;7:187-203.
46. Klepstad P, Maurset A, Ratti Moberg E, Øye I. Evidence of a role for NMDA receptors in pain perception. Eur J Pharmacol 1990;187:513-518.
47. Ryder S, Way WL, Trevor AJ. Comparative pharmacology of the optical isomers of ketamine in mice. Eur J Pharmacol 1978;49:15-23.
48. Lakin ML, Winters WD. Behavioral correlates of naloxone inhibition of analgesia induced by various CNS excitatory drugs in the rat. Proc West Pharmacol Soc 1978;21:27-30.
49. Finck AD, Ngai SM. Opiate receptor mediation of ketamine analgesia. Anesthesiology 1982;56:291-297.
50. Smith DJ, Bouchai RL, De Sanctis CA, et al. Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology 1987;26:1253-1260.
51. Seth S, Mukherjee D, Roy Choudhary AK, Sinha JN, Gurtu S. Opioid and non-opioid central cardio-vascular effects of ketamine. Naunyn-Schmiederberg's Arch Pharmacol 1990;342:535-538.
52. Latasch L, Freye E. Opioid receptors-mediated respiratory effects and antinociception after S(+)-ketamine. Acta Anaesth Belg 1993;44:93-102.
53. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL. Selective activation of dopaminergic pathways in the mesocortex by compounds that act at the phencyclidine (PCP) binding site: tentative evidence for PCP recognition sites not coupled to N-methyl-D-aspartate (NMDA) receptors. Neuropharmacology 1990;29:225-230.
54. Verma A, Kulkarni SK. Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology 1992;107:431-436.
55. 10 dopamine neurons. Neurosci Lett 1990;119:159-162.
56. 3H]1-[2-(2-thienyl)cyclohexyl]piperidine labels two high-affinity binding sites in human cortex: further evidence for phencyclidine binding sites associated with the biogenic amine reuptake complex. Synapse 1991;8:289-300.
57. 3H]BTCP}: a new phencylcidine analog selective for the dopamine uptake complex. Eur J Pharmacol 1988;148:427-436.
58. Cook DJ, Carton EG, Housmans PR. Mechanism of the positive inotropic effect of ketamine in isolated ferret ventricular papillary muscle. Anesthesiology 1991;74:880-883.
59. Meliska CJ, Trevor AJ. Differential effects of ketamine on schedule-controlled responding and motilitv. Pharmacol Biochem Behav 1978;8:679-683.
60. Cumming JF. The development of an acute tolerance to ketamine. Anesth Analg 1976;55:788-791.
61. Manohar S, Maxwell D, Winters WD. Development of EEG seizure activity during and after chronic ketamine administration in the rat. Neuropharmacology 1972;11:819-826.
62. Wessinger WD, Owens SM. Phencyclidine dependence: the relationship of dose and serum concentrations to operant behavioral effects. J Pharmacol Exp Ther 1991;258:207-215.
63. Spain JW, Klingman GI. Continuous intravenous infusion of phencyclidine in unrestrained rats results in the rapid induction of tolerance and physical dependence. J Pharmacol Exp Ther 1985;234:415-424.
64. Smith JA, Santer LJ. Respiratory arrest following intramuscular ketamine injection in a 4-year-old child. Ann Emerg Med 1993;22:613-615.
65. Modica PA, Tempelhoff R, White PF. Pro- and anticonvulsant effects of anesthetics (Part II). Anesth Analg 1990;70:433-444.
66. Chen G, Ensor CR, Bohner B. The neuropharmacology of 2-(o-chlorophenyl)-2-methylaminocyclohexanone hydrochloride. J Pharmacol Exp Ther 1966;152:332-339.
67. Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology 1989;39:1037-1039.
68. Seigel RK. PCP and violent crime: the people vs peace. In: Smith D, Wesson DR, Buxton ME, Seymour RB, Ross S, Bishop MP, Zerkin E, eds. PCP: problems and prevention. Iowa: Kendall/Hunt Publishing Company, 1982:124-137.
69. Fauman MA, Fauman BJ. Chronic phencyclidine (PCP) abuse: a psychiatric perspective. In: Smith D, Wesson DR, Buxton ME, Seymour RB, Ross S, Bishop MP, Zerkin E, eds. PCP: problems and prevention. Iowa: Kendall/Hunt Publishing Company, 1982:115-123.